SUMMARY

The version of California Senate Bill (SB) 90 analyzed by the California Health Benefits Review Program (CHBRP) would limit cost sharing (copayments, coinsurance, and deductibles) for insulin to $35 for a 30-day supply.

In 2024, of the 22.8 million Californians enrolled in state-regulated health insurance, 14 million would have insurance subject to, and potentially impacted by, SB 90.

Benefit Coverage: At baseline there are 123,442 enrollees who use insulin, where 68,344 enrollees using insulin have cost sharing that does not exceed the SB 90 cost-sharing cap (55%) and 55,098 enrollees using insulin have cost sharing that exceeds the SB 90 cap (45%). Postmandate, 100% of enrollees with cost sharing that exceeds the cap at baseline would have cost sharing below the cap. SB 90 does not to exceed the definition of essential health benefits (EHBs) in California.

Medical Effectiveness: CHBRP found a preponderance of evidence that higher cost sharing reduces adherence to insulin therapy and lower cost sharing increases adherence to insulin. There is insufficient evidence on the associated effect of cost sharing for insulin on diabetes-related health outcomes, including HbA1c levels, outpatient visits, emergency department visits, hospitalizations, long-term complications, and disability/absenteeism rates.

Cost and Health Impacts: The 45% of enrollees with cost sharing that exceeds the cap at baseline would experience a 67% reduction in cost sharing, which results in a 6.6% increase in utilization of insulin postmandate for those enrollees. Average cost sharing for these enrollees decreases from $61 per prescription to $20 per prescription. In 2024, SB 90 would increase total net annual expenditures by $30,028,000 or 0.02% for enrollees with plans regulated by the California Department of Managed Health Care (DMHC) and policies regulated by the California Department of Insurance (CDI). This is due to an increase in $62,458,000 in total health insurance premiums paid by employers and enrollees, and a $32,430,000 decrease in enrollee expenses.

Additionally, CHBRP assumed a 10% decrease in diabetes-related emergency department visits due to increased insulin utilization stemming from better adherence to insulin prescription regimens for those who underuse. Offsets stemming from this reduction in diabetes-related emergency department visits are estimated to result in $2,495,000 million lower allowed costs postmandate in 2024.

SB 90 may result in improved glycemic control, a reduction in healthcare utilization, a reduction in long-term complications attributable to diabetes, and improved quality of life for enrollees that experience a decrease in cost sharing and improved insulin adherence, or begin using insulin due to reduced costs.

CONTEXT

Diabetes mellitus (DM), frequently referred to as diabetes, is one of the most common chronic conditions in California and the United States. According to the 2021 data from the Behavioral Risk Factor Surveillance System, about 12% of the adult population in California has been diagnosed with diabetes. The incidence of diabetes is highest among adults aged 65 and older.

Diabetes is a chronic disease with short- and long-term health effects that prevent the proper production of and/or response to insulin, a hormone that facilitates the transfer of glucose into cells to provide energy. Insulin can be used to treat all three types of diabetes: Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM), and gestational diabetes (GDM). The American Diabetes Association recommends different insulin regimens based on the type of diabetes a person has. Insulin is necessary for the treatment of T1DM and and other aspects of health make stability of impacts less certain as time goes by.

1 Similar cost and health impacts could be expected for the following year, though possible changes in medical science

2 Refer to CHBRP's full report for full citations and references.
sometimes necessary for the treatment of T2DM and GDM.

In general, insulin has become expensive for individuals living with diabetes; therefore, cost may be a barrier to insulin use for some individuals. Other identified barriers to insulin use that are independent of cost include regimen complexity and treatment tolerability, as well as injection-related factors.

**BILL SUMMARY**

Senate Bill (SB) 90 would limit allowed cost sharing (copayments, coinsurance, and deductibles) for insulin to $35 for a 30-day supply. SB 90 specifies that for high deductible health plans (HDHPs) the cost sharing limit only applies to insulin prescriptions should HSA-eligible HDHPs elect to cover insulin predeductible according to federal law.

Figure A notes how many Californians have health insurance that would be subject to SB 90.

**Figure A. Health Insurance in CA and SB 90**

<table>
<thead>
<tr>
<th>Category</th>
<th>Number of Enrollees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Subject to Mandate</td>
<td>20,000,000</td>
</tr>
<tr>
<td>State-Regulated Health Insurance Subject to Mandate</td>
<td>15,000,000</td>
</tr>
<tr>
<td>Federally Regulated (Medicare beneficiaries, enrollees in self-insured products, etc)</td>
<td>10,000,000</td>
</tr>
<tr>
<td>Uninsured</td>
<td>5,000,000</td>
</tr>
<tr>
<td>Medi-Cal (DMHC Regulated)</td>
<td>25,000,000</td>
</tr>
</tbody>
</table>

Notes: *Medicare beneficiaries, enrollees in self-insured products, etc.

**IMPACTS**

**Benefit Coverage, Utilization, and Cost**

**Benefit Coverage**

CHBRP estimates at baseline there are 123,442 enrollees who use insulin in commercial and CalPERS DMHC-regulated plans and CDI-regulated policies, where 68,344 enrollees using insulin have cost sharing that does not exceed the SB 90 cost-sharing cap (55%). CHBRP estimates 55,098 enrollees (45%) using insulin have cost sharing that exceeds the SB 90 cap. Postmandate, 100% of enrollees with cost sharing that exceeds the cap at baseline would have cost sharing below the cap.

**Utilization**

Postmandate, the group whose claims exceeded the cost-sharing cap at baseline would experience an increase in utilization because this group would experience a decrease in cost sharing due to the bill. Utilization among enrollees who exceeded the cap at baseline is higher than those under the cap, which reflects the greater need for insulin in this group of enrollees.

To estimate changes in utilization postmandate, CHBRP applied an estimate of price elasticity of demand to enrollees exceeding the cap at baseline. CHBRP assumes that utilization decreases by 8% when cost-sharing doubles. Based on this assumption, CHBRP estimates a 67% reduction in cost sharing for those enrollees who have cost sharing exceeding the cost-sharing cap at baseline, and therefore estimates a 6.6% increase in utilization of insulin postmandate for those enrollees.

**Expenditures**

Based on Milliman’s 2021 Consolidated Health Cost Guidelines Sources Database (CHSD) claims data, the average cost of insulin per prescription per month is $521. For enrollees whose claims do not exceed the cost-sharing cap at baseline, the average cost sharing for insulin is $13, and for those enrollees whose claims exceed the cost-sharing cap at baseline, the average cost sharing for insulin is $61. Postmandate, cost sharing for enrollees who had claims exceeding the cap would experience a 67% reduction in cost sharing, resulting in an average cost share of $20 per month.

SB 90 would increase total net annual expenditures by $30,028,000 or 0.02% for enrollees with DMHC-
regulated plans and CDI-regulated policies. This is due to an increase in $62,458,000 in total health insurance premiums paid by employers and enrollees due to the cost-sharing cap, adjusted by a $32,430,000 decrease in enrollee expenses. CHBRP estimates that total premiums for non-CalPERS employers purchasing group health insurance would increase by $34,151,000, or 0.06%. Total premiums for purchasers of individual market health insurance would increase by $17,359,000, or 0.08%. Changes in premiums as a result of SB 90 would vary by market segment. The greatest change in premiums as a result of SB 90 is for small-group (0.10% increase) and individual (0.08%) plans in the DMHC-regulated market and small-group (0.09% increase) and individual (0.08% increase) in the CDI-regulated market.

Based on the medical effectiveness review, which examined the literature on outcomes associated with better adherence to insulin, CHBRP assumed a 10% decrease in diabetes-related emergency department visits due to increased insulin utilization stemming from better adherence to insulin prescription regimens for those who underuse. Offsets stemming from this reduction in diabetes-related emergency department visits are estimated to result in $2,495,000 lower allowed costs postmandate in 2024.

**Figure B. Expenditure Impacts of SB 90**

<table>
<thead>
<tr>
<th>Plan Type</th>
<th>Premiums</th>
<th>Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employer Premiums</td>
<td>$34,151,000</td>
<td>$0</td>
</tr>
<tr>
<td>Individual Premiums</td>
<td>$17,359,000</td>
<td>$0</td>
</tr>
<tr>
<td>Employee Premiums</td>
<td>$10,948,000</td>
<td>$0</td>
</tr>
<tr>
<td>DMHC-regulated Medi-Cal Managed Care Plan Expenditures</td>
<td>N/A</td>
<td>$-32,430,000</td>
</tr>
<tr>
<td>Cost-Sharing for Covered Benefits</td>
<td>$0</td>
<td></td>
</tr>
<tr>
<td>Enrollee Expenses for Non-Covered Benefits</td>
<td>$0</td>
<td></td>
</tr>
</tbody>
</table>

*Source: California Health Benefits Review Program, 2023.*

**Enrollee Cost-Sharing Expenses**

For baseline insulin users, SB 90 caps on cost sharing only impact those enrollees who are above the cap at baseline. Overall, 45% of enrollees who use insulin at baseline would experience changes in cost sharing.

It is possible that some enrollees who had deferred insulin treatment due to cost could begin using insulin postmandate; thus, this group of enrollees would incur cost sharing postmandate, whereas they did not have cost sharing at baseline. However, this group is estimated to be relatively small. Literature suggests approximately 2.5% of people who were prescribed insulin never started their prescription in the past year due to cost. Thus, for some enrollees, cost sharing may be the sole barrier to filling their insulin prescription.

The enrollees most likely to experience the greatest cost-sharing reductions postmandate are those who are enrolled in plans that require significant deductibles to be met before coinsurance or copayment is applied to the insulin purchase. Cost-sharing reductions due to SB 90 are the greatest for enrollees who have the highest cost sharing for insulin at baseline. Among the enrollees impacted by the cost-sharing cap, enrollees with cost-sharing expenditures for insulin in the top 1% at baseline have an annual savings of greater than $1,852.

**Covered California — Individually Purchased**

Enrollees with coverage purchased through Covered California would experience an average reduction in cost sharing of $0.29 per member per month and an increase in premiums of $0.51 per member per month. This results in a total change in expenditures of 0.03%.

**Medi-Cal**

Because SB 90 only impacts DMHC-regulated pharmacy benefits, Medi-Cal managed care plans are not subject to the provisions of SB 90.

**CalPERS**

For CalPERS HMO enrollees, the impact on premiums is $0, because there are no enrollees for whom cost sharing for insulin prescriptions is higher than the cap at baseline.

**Number of Uninsured in California**

Because the change in average premiums does not exceed 1% for any market segment, CHBRP would expect no measurable change in the number of uninsured persons due to the enactment of SB 90.
Medical Effectiveness

CHBRP found a preponderance of evidence from seven cross-sectional and retrospective studies on cost-related insulin use/adherence that cost sharing affects insulin use and adherence in patients with diabetes. These studies provided a preponderance of evidence that higher cost sharing reduces adherence to insulin, and lower cost sharing increases adherence to insulin.

CHBRP found insufficient evidence on the associated effect of cost sharing for insulin on diabetes-related health outcomes, including HbA1c levels, outpatient visits, emergency department visits, hospitalizations, long-term complications, and disability/absenteeism rates overall. Though the studies presented did report on these health and utilization outcomes, the findings were not specific to the effect of insulin alone but combined with use of other oral antidiabetic medications and testing supplies.

There were several limitations that contributed to the gradings provided in this review, most notably the inherent differences between the types of diabetes conditions and the multifaceted nature of diabetes treatment. This resulted in a literature base that is not as rigorous and thereby limiting the certainty of conclusions drawn from the evidence.

Public Health

In the first year postmandate, 55,098 enrollees who exceed the insulin cost-sharing cap at baseline would have reduced cost sharing. CHBRP projects that as a result, there would be a 6.6% increase in utilization of insulin among these enrollees. CHBRP found a preponderance of evidence that cost sharing for insulin is effective in improving adherence to insulin in patients with diabetes, and insufficient evidence on the effect of cost sharing for diabetes-related health outcomes. Therefore, SB 90 may result in improved glycemic control, a reduction in healthcare utilization such as emergency department visits, a reduction in long-term complications attributable to diabetes, and improved quality of life for enrollees that experience a decrease in cost sharing and improved insulin adherence or begin using insulin due to reduced costs.

Long-Term Impacts

CHBRP estimates annual insulin utilization after the initial 12 months from the enactment of SB 90 would likely stay similar to utilization estimates during the first 12 months postmandate. Health care utilization due to improved diabetes management may change in the long term. Reductions in significant complications or comorbidities may take years to develop but are not trivial.

Similarly, significant differences in disability and absenteeism may also take years to develop. SB 90 is unlikely to impact these public health outcomes statewide, but at a person-level it could make a substantial difference in long-term healthcare spending, morbidity, and mortality.

CHBRP estimates that SB 90 would improve disparities related to income for some enrollees who have cost-related barriers to insulin use. CHBRP is unable to estimate reductions in existing disparities. However, because the prevalence of diabetes is higher for Black people than for White people, and there is evidence that cost-related medication nonadherence is also higher among Black people, it is possible that this disparity may be reduced for the population SB 90 impacts.

Because of the lack of evidence that reduced cost sharing for insulin reduces mortality, the impact of SB 90 on premature mortality is unknown. However, well-controlled blood glucose results in fewer diabetes-related comorbidities (blindness, amputations, kidney disease, etc.). Therefore, for those patients who attain good glycemic control through increased adherence to insulin, these diabetes-related comorbidities that are known to lead to premature death could be prevented, delayed, or ameliorated.

Essential Health Benefits and the Affordable Care Act

SB 90 would not require coverage for a new state benefit mandate and instead modifies cost-sharing terms and conditions of an already covered medication. Therefore, SB 90 does not exceed the definition of EHBs in California.